Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06845878 · ClinicalTrials.gov registry record · Phase 1
A Chatbot to Support Substance Use Recovery
A Phase 1 study of Opiate Substitution Treatment and Opiate-Related Disorders, sponsored by Dimagi.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 55
- Enrollment target
- 1
- Study location
NCT06845878 is a Phase 1 study of Opiate Substitution Treatment and Opiate-Related Disorders that is actively recruiting participants, run by Dimagi. The registered enrollment target is 55 participants, below the 415-participant average among 3 other Opiate Substitution Treatment trials with a reported enrollment target (87% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06845878, a Phase 1 study of Opiate Substitution Treatment and Opiate-Related Disorders, is actively recruiting participants, sponsored by Dimagi.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 55 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this clinical trial is to learn if/how an AI chatbot can support patients who in recovery for substance use, specifically those who are receiving medication for opioid use disorder. Can the chatbot help lower drug use? Can the chatbot help improve clinical appointment adherence? Can the chatbot help patients build self-efficacy in leading their own recovery journey? Will the chatbot help reduce workload burden for primary care teams? Can the chatbot serve as a safe, useful and engaging tool to support patients? Researchers will investigate the effects of using a chatbot to support follow-up care for patients in opioid use recovery. Participants will: * Receive access to a chatbot for 12 weeks that they can use to prepare for upcoming clinical appointments, find community resources, learn about urge-surfing and wellness techniques, and query for assistance with other recovery-related information and tasks * Complete surveys and provide user feedback
Conditions Studied
Interventions
- OTHER chatbot
Study Locations (1)
Massachusetts
- Massachusetts General Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 55 participants |
| Start Date | 2025-03-07 |
| Est. Completion | 2025-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06845878
The ClinicalTrials.gov registry entry for NCT06845878 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 55 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 415-participant average among 3 other Opiate Substitution Treatment trials with a reported enrollment target (87% lower). The listed sponsor is Dimagi, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Opiate Substitution Treatment appearing as the primary indexed condition, and to 1 intervention - of which chatbot is the first listed.
NCT06845878 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT06845878 about?
NCT06845878 is a clinical study titled "A Chatbot to Support Substance Use Recovery". The goal of this clinical trial is to learn if/how an AI chatbot can support patients who in recovery for substance use, specifically those who are receiving medication for opioid use disorder. Can the chatbot help lower drug use? Can the chatbot help improve clinical appointment adherence? Can the...
What is the current status of trial NCT06845878?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 55 participants. The study started on 2025-03-07. Estimated completion is 2025-09.
What conditions does trial NCT06845878 study?
This clinical trial studies the following conditions: Opiate Substitution Treatment, Opiate-Related Disorders.
What interventions are being tested in trial NCT06845878?
The interventions under investigation include: chatbot (OTHER).
Who is sponsoring clinical trial NCT06845878?
This trial is sponsored by Dimagi, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06845878 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Opiate Substitution Treatment
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Neurocognitive Mechanisms Underlying Smartphone-Assisted Prevention of Relapse in Opioid Use Disorder
RECRUITING · Phase 2
-
Kentucky Outreach Service Kiosk (KyOSK): Reducing HIV, HCV, and Overdose Risk
ACTIVE NOT RECRUITING · NA
-
Buprenorphine and Substance Abuse Services for Prescription Opioid Dependence
COMPLETED · NA
Explore more on PlainTrial
Opiate Substitution Treatment
All registered trials for this condition
Opiate-Related Disorders
All registered trials for this condition
Massachusetts
All trials with a study site in Massachusetts
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.